Showing 1,501 - 1,520 results of 116,717 for search '(( a non decrease ) OR ( 5 ((((wt decrease) OR (we decrease))) OR (a decrease)) ))', query time: 2.08s Refine Results
  1. 1501

    Image2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  2. 1502

    Table2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.DOCX by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  3. 1503

    Image11_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  4. 1504

    Image3_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  5. 1505

    Image13_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  6. 1506

    Image14_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  7. 1507

    Image1_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  8. 1508

    Severe decreases of TECs and impaired TEC expansion in the absence of mTORC1/Raptor. by Hong-Xia Wang (288934)

    Published 2016
    “…The gating strategy is shown in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1002370#pbio.1002370.s003" target="_blank">S2 Fig</a>. …”
  9. 1509
  10. 1510
  11. 1511

    Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  12. 1512

    Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  13. 1513

    Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  14. 1514

    Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  15. 1515

    Image 7_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
  16. 1516

    Image 6_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
  17. 1517

    Image 3_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
  18. 1518

    Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
  19. 1519

    Image 2_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
  20. 1520

    Image 4_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”